An adjuvant autologous therapeutic vaccine %28HSPPC-96%3B vi…
An adjuvant autologous therapeutic vaccine %28HSPPC-96%3B vitespen%29 versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma%3A a multicentre%2C open-label%2C randomised phase III trial.
Article, Chapter
Full text availability for this item
Journal:
Lancet, TheOpens in new Window
Coverage:
- 1823-10-05~present; volume:1~present;issue:1~present